Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
09/15/2021 - 08:05 AM
- Live webcast presentation on Wednesday, September 22 nd at 10:45 AM ET
GAINESVILLE, Fla. --(BUSINESS WIRE)--
Cyclo Therapeutics, Inc. N. Scott Fine , Chief Executive OfficerSharon Hrynkow , PhD, Chief Scientific Officer and Senior Vice President for Medical AffairsCyclo Therapeutics , will present at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021 at 10:45 AM ET .
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
The live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website (www.cyclotherapeutics.com ). The webcast replay will be archived for 90 days following the live presentation.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe , is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547 , NCT02912793 , NCT03893071 and NCT04860960 ). The Company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842 ). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20210915005076/en/
Investor Contact:
JTC Team, LLC
Jenene Thomas
CYTH@jtcir.com
Source: Cyclo Therapeutics, Inc.
CYTH Rankings
#4676 Ranked by Stock Gains
CYTH Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About CYTH
cyclodextrin technologies development, inc. (ctd), the "company", was organized as a florida corporation on august 9, 1990 with operations beginning july, 1992. in may of 1994 the company became a fully reporting public company listed on the otc bb under the symbol ctdi. in 2000, the company altered its corporate structure to a holding company with subsidiary companies. the otc bb symbol was changed to ctdh. ctd holdings, inc. (the "company") was originally formed to market and sell cyclodextrins and related products to the food, pharmaceutical, and other industries; it also provided consulting services related to cyclodextrin technology. ctdh, as a holding company, will acquire, create, and invest in companies that will develop, market, and/or sell products containing cyclodextrins. the company currently operates four wholly owned subsidiaries: ctd, inc.; nanosonic products, inc.; sphingo biotech, inc.; and ferrazo environmental technologies, inc.
